98 related articles for article (PubMed ID: 36427327)
1. Decline of cytology-based cervical cancer screening for COVID-19: a single-center Peruvian experience.
Rojas-Zumaran V; Walttuoni-Picón E; Campos-Siccha G; Cruz-Gonzales G; Huiza-Espinoza L; Moya-Salazar J
Medwave; 2022 Nov; 22(10):e2589. PubMed ID: 36427327
[TBL] [Abstract][Full Text] [Related]
2. Impact of the COVID-19 Pandemic on Cervical Cancer Screening in São Paulo State, Brazil.
Martins TR; Witkin SS; Mendes-Corrêa MC; Godoy AS; Cury L; Balancin ML; Ab'Saber AM; Peres SV; Messias S; Tozetto Mendoza TR; Longatto-Filho A
Acta Cytol; 2023; 67(4):388-394. PubMed ID: 36682351
[TBL] [Abstract][Full Text] [Related]
3. COVID-19 and inequities in colorectal and cervical cancer screening and diagnosis in Washington State.
Amram O; Amiri S; Robison J; Pflugeisen CM; Monsivais P
Cancer Med; 2022 Aug; 11(15):2990-2998. PubMed ID: 35304835
[TBL] [Abstract][Full Text] [Related]
4. [The ecologization of the Papanicolaou stain in the diagnosis of cervical cancer].
Rojas-Zumaran V; Moya-Salazar J
Rev Med Inst Mex Seguro Soc; 2018 Oct; 56(3):217-225. PubMed ID: 30365481
[TBL] [Abstract][Full Text] [Related]
5. The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women.
Goldie SJ; Weinstein MC; Kuntz KM; Freedberg KA
Ann Intern Med; 1999 Jan; 130(2):97-107. PubMed ID: 10068381
[TBL] [Abstract][Full Text] [Related]
6. Frequency of high-grade squamous cervical lesions among women over age 65 years living with HIV.
Massad LS; Xie X; Minkoff HL; Michel KG; D'Souza G; Wang CC; Konkle-Parker D; Ofotokun I; Fischl MA; Rahangdale L; Strickler HD
Am J Obstet Gynecol; 2021 Oct; 225(4):411.e1-411.e7. PubMed ID: 33957115
[TBL] [Abstract][Full Text] [Related]
7. Cervical cancer risk and screening among women seeking assistance with basic needs.
Kuroki LM; Massad LS; Woolfolk C; Thompson T; McQueen A; Kreuter MW
Am J Obstet Gynecol; 2021 Apr; 224(4):368.e1-368.e8. PubMed ID: 33316278
[TBL] [Abstract][Full Text] [Related]
8. Eco-Pap: The Ecological Modification of the Papanicolaou Stain for Sustainable Cervical Cancer Diagnosis.
Moya-Salazar J; Rojas-Zumaran V
Acta Cytol; 2019; 63(1):35-43. PubMed ID: 30352442
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and factors associated with cervical cancer preventive screening in a Peruvian region.
Becerra-Canales B; Campos M; Atuncar-Deza S; Cáceres-Yparraguirre H
Medwave; 2023 Sep; 23(8):. PubMed ID: 37748197
[TBL] [Abstract][Full Text] [Related]
10. Regional variation in histopathology-specific incidence of invasive cervical cancer among Peruvian women.
Pierce Campbell CM; Curado MP; Harlow SD; Soliman AS
Int J Gynaecol Obstet; 2012 Jan; 116(1):47-51. PubMed ID: 22036058
[TBL] [Abstract][Full Text] [Related]
11. The impact of the COVID-19 pandemic on the Ontario Cervical Screening Program, colposcopy and treatment services in Ontario, Canada: a population-based study.
Meggetto O; Jembere N; Gao J; Walker MJ; Rey M; Rabeneck L; Murphy KJ; Kupets R;
BJOG; 2021 Aug; 128(9):1503-1510. PubMed ID: 33982870
[TBL] [Abstract][Full Text] [Related]
12. [Health technology assessment report: Computer-assisted Pap test for cervical cancer screening].
Della Palma P; Moresco L; Giorgi Rossi P
Epidemiol Prev; 2012; 36(5 Suppl 3):e1-43. PubMed ID: 23139174
[TBL] [Abstract][Full Text] [Related]
13. Age at last screening and remaining lifetime risk of cervical cancer in older, unvaccinated, HPV-negative women: a modelling study.
Malagón T; Kulasingam S; Mayrand MH; Ogilvie G; Smith L; Bouchard C; Gotlieb W; Franco EL
Lancet Oncol; 2018 Dec; 19(12):1569-1578. PubMed ID: 30392810
[TBL] [Abstract][Full Text] [Related]
14. Point-of-Care Digital Cytology With Artificial Intelligence for Cervical Cancer Screening in a Resource-Limited Setting.
Holmström O; Linder N; Kaingu H; Mbuuko N; Mbete J; Kinyua F; Törnquist S; Muinde M; Krogerus L; Lundin M; Diwan V; Lundin J
JAMA Netw Open; 2021 Mar; 4(3):e211740. PubMed ID: 33729503
[TBL] [Abstract][Full Text] [Related]
15. Socio-demographic inequalities in the uptake of Papanicolaou tests in Peru: analysis of the 2015-2017 Demographic and Family Health Survey.
Barrenechea-Pulache A; Avila-Jove E; Hernández-Vásquez A; Runzer-Colmenares FM
Epidemiol Health; 2020; 42():e2020043. PubMed ID: 32580534
[TBL] [Abstract][Full Text] [Related]
16. Attendance at cervical cancer screening and use of diagnostic and therapeutic procedures on the uterine cervix assessed from individual health insurance data (Belgium, 2002-2006).
Arbyn M; Fabri V; Temmerman M; Simoens C
PLoS One; 2014; 9(4):e92615. PubMed ID: 24690620
[TBL] [Abstract][Full Text] [Related]
17. Cervical Cancer Screening-Past, Present, and Future.
Wentzensen N; Clarke MA
Cancer Epidemiol Biomarkers Prev; 2021 Mar; 30(3):432-434. PubMed ID: 33857013
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the Accuracy of Papanicolaou Test Cytology, Visual Inspection With Acetic Acid, and Visual Inspection With Lugol Iodine in Screening for Cervical Neoplasia in Southeast Nigeria.
Egede J; Ajah L; Ibekwe P; Agwu U; Nwizu E; Iyare F
J Glob Oncol; 2018 Sep; 4():1-9. PubMed ID: 30241249
[TBL] [Abstract][Full Text] [Related]
19. Performance of papanicolaou testing and detection of cervical carcinoma in situ in participants of organized cervical cancer screening in South Korea.
Han MA; Choi KS; Lee HY; Jun JK; Jung KW; Kang S; Park EC
PLoS One; 2012; 7(4):e35469. PubMed ID: 22530028
[TBL] [Abstract][Full Text] [Related]
20. Feasibility of management of high-grade cervical lesions in a single visit: a randomized controlled trial.
Brewster WR; Hubbell FA; Largent J; Ziogas A; Lin F; Howe S; Ganiats TG; Anton-Culver H; Manetta A
JAMA; 2005 Nov; 294(17):2182-7. PubMed ID: 16264159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
